Related Experiment Video

Updated: Apr 28, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

8.9K

Selective and potent small-molecule inhibitors of PI3Ks

Yujeong Jeong1, Daeil Kwon, Sungwoo Hong

  • 1Center for Catalytic Hydrocarbon Functionalizations, Institute of Basic Science, Daejeon 305-701, Korea.

Future Medicinal Chemistry
|June 20, 2014
PubMed

Insights

Developing selective phosphoinositide 3-kinase (PI3K) inhibitors is crucial for cancer therapy. This review highlights advances in designing PI3K-selective drugs to minimize toxicity and improve cancer treatment outcomes.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Oncology

Background:

  • Class I phosphoinositide 3-kinases (PI3Ks) comprise four variants: p110α, p110β, p110δ, and p110γ.
  • The PI3K pathway is frequently activated in various human cancers, making it a key therapeutic target.
  • Developing selective kinase inhibitors is challenging due to potential off-target activities and toxicity.

Purpose of the Study:

  • To review the current progress in developing selective PI3K inhibitors.
  • To highlight strategies for achieving PI3K selectivity over other protein kinases.
  • To emphasize the role of structural information in inhibitor design.

Main Methods:

  • Literature review of PI3K inhibitor development.
  • Analysis of recent advances in selective PI3K inhibitor design.
  • Focus on structural insights guiding selectivity.

Main Results:

  • Significant progress has been made in developing PI3K-selective inhibitors.
  • Structural information is key to understanding and designing selective inhibitors.
  • Achieving selectivity remains a critical challenge in drug discovery.

Conclusions:

  • Selective PI3K inhibitors hold promise for cancer treatment.
  • Continued research into structural biology and medicinal chemistry is essential.
  • Overcoming selectivity challenges will improve drug safety and efficacy.

More Related Videos

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

287
Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

5.7K

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
10.1K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
7.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
57
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
15.2K